Immuneering (IMRX) Income towards Parent Company (2020 - 2026)

Immuneering's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$32.1 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 110.46% year-over-year to -$32.1 million; the TTM figure through Mar 2026 stood at -$108.7 million (down 45.18% YoY), while the FY2025 annual figure was -$129.7 million, down 7.67% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$32.1 million, down from -$12.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$12.1 million in Q4 2025, with the low at -$44.5 million in Q3 2025.
• The 5-year median for Income towards Parent Company is -$19.4 million (2022), against an average of -$22.3 million.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company slumped 188.98% in 2022, then surged 40.55% in 2024.
• Immuneering's Income towards Parent Company stood at -$13.6 million in 2022, then declined by 15.75% to -$15.7 million in 2023, then declined by 16.43% to -$18.3 million in 2024, then soared by 34.08% to -$12.1 million in 2025, then tumbled by 165.32% to -$32.1 million in 2026.
• Business Quant data shows IMRX's Income towards Parent Company at -$32.1 million in Q1 2026, -$12.1 million in Q4 2025, and -$44.5 million in Q3 2025.